No Data
Wanbang Pharmaceutical: 2024 Annual Report
Wanbang Pharmaceutical: 2024 Annual Report Summary
Wanbang Pharmaceutical: Report for the first quarter of 2025
Wanbang Pharmaceutical (301520.SZ) released its first-quarter results, with a net income of 11.8493 million yuan, a decrease of 60.09%.
Wanbang Pharmaceutical (301520.SZ) released the first quarter report for 2025, with the company's revenue of 7105...
Wanbango Pharmaceutical (301520.SZ): The international tariff policy has not yet had a direct adverse impact on the company.
On April 10, Glorium Exchange reported that Wanbang Pharmaceutical (301520.SZ) stated on the interactive platform that the company currently has no overseas Business and that international tariff policies have not yet had a direct adverse effect on the company.
CEO Chunlei Tao, Anhui Wanbang Pharmaceutical Technology Co.,Ltd.'s (SZSE:301520) Largest Shareholder Sees Value of Holdings Go Down 14% After Recent Drop
